Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Frey NV. Blood 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Frey NV. Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.
PMID: 35507688